Novartis: Bone Diseases, Metabolic trials

The registry lists 11 Bone Diseases, Metabolic studies with Novartis as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 2 2Phase 3 7Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.CompletedNCT00171340Phase 3Results posted
• Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and OlderCompletedNCT00132808Phase 3Results posted
• Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal TherapyCompletedNCT00050011Phase 3Results posted
• A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.CompletedNCT00738257Phase 4
• To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal WomenCompletedNCT00145275Phase 3
• Safety and Efficacy of AAE581 in Postmenopausal Women With OsteoporosisCompletedNCT00100607Phase 2
• A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral BisphosphonateCompletedNCT00100555Phase 3
• Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic AcidCompletedNCT00097812Phase 3
• The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation TherapyCompletedNCT00063609Phase 4
• Bisphosphonate Treatment of Osteogenesis ImperfectaCompletedNCT00063479Phase 2
• Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip FractureCompletedNCT00046254Phase 3